Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Supplemental Cash Flow Information [Abstract]
Cash paid for interest	$ 101,000	$ 128,000
Impact of adoption of lease accounting standards		1,616,000
Gain from change in fair value of interest rate swap derivatives		7,000
Common stock issued upon conversion of convertible note		500,000
Equity issued to purchase intangible assets		145,000
Common A Shares issued for marketing services	210,000
Common A Shares issued for Impact BioMedical	3,132,000
Series A Preferred Shares issued for Impact BioMedical	35,187,000
Long-lived assets acquired through settlement of notes receivable	$ 838,000